INTERIM REPORT JANUARY-MARCH 2012 CHRONTECH PHARMA AB

  · Research and development costs amounted to SEK 3.2 (3.8) m
  · The loss
after tax was SEK -4.2 (-5.0) m
  · Earnings per share were SEK -0.02 (-0.06)
· The company had no net sales for the period
  · The controlled phase II
clinical study of ChronVac-C® in combination with standard-of-care is
ongoing.

For more information, please contact:

Anders Vahlne, CEO and Head
of Research, ChronTech Pharma AB

Mobile phone: +46 709 28 05 28,
E-mail:
anders.vahlne@ki.se

About ChronTech

ChronTech develops the therapeutic DNA
vaccines ChronVac-C® and ChronVac-B drugs against chronic hepatitis C virus and
hepatitis B virus infections, i.e. chronic infections with jaundice causing
viruses which can lead to liver cirrhosis and liver cancer. ChronTech has also
developed and further develops a patent pending new type of injection needle for
a more effective uptake of DNA vaccines. ChronTech also have part ownership in
the wound healing therapy ChronSeal®, and in the new platform technology RAS®.
The ChronTech share is admitted to trade on First North. Remium Nordic AB is
Certified Adviser for ChronTech. For more information, please visit:
www.chrontech.se

In the event of any discrepancy between the Swedish and
English versions of this press release, the Swedish version will take
precedence.